Latest Breaking News On - Frontier medicines - Page 1 : vimarsana.com

PennyMac Mortgage Investment Trust Announces SiSi Pouraghabagher Joined Its Board of Trustees

PennyMac Mortgage Investment Trust Announces SiSi Pouraghabagher Joined Its Board of Trustees
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesDavid spectorLuis obispoSisi pouraghabagherAuto financial corporationPennymac mortgage investment trustPennymac mortgage investmentBoard of trusteesAudit committeePennymac financial services incCalifornia polytechnic state universityCapital managementChief executive officer davidAudit committee chairPrivate bancorpFrontier medicines

AACR: KRAS inhibitors pop in preclinical data debuts

AACR: KRAS inhibitors pop in preclinical data debuts
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoAndrew krivoshikAmgen lumakrasJohns hopkins universityAmerican association for cancer researchBristol myers squibbVerastem oncologyFrontier medicinesQuanta therapeuticsAmerican associationCancer researchGenfleet therapeuticsRevolution medicineMirati therapeutics

Adagrasib, Cetuximab May Benefit KRASG12c Colorectal Cancer Patients

Adagrasib, Cetuximab May Benefit KRASG12c Colorectal Cancer Patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesRedx pharmaDaiichi sankyoBristol myers squibb medarexGenentech rocheEli lillyScott kopetzNavire pharmaAstrazeneca medimmuneLutris pharmaUniversity of texas md anderson cancer centerHarbinger healthGilead sciencesGuardant healthAmerican association for cancer researchSerono inc

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

United statesSan diegoDaiichi sankyoBristol meyers squibbRedx pharmaEli lillyNavire pharmaGenentech rocheScott kopetzAstrazeneca medimmuneLutris pharmaBristol myers squibb medarexBayer healthDrug administrationIylon precision oncologyGilead sciences

InnovationRx: Exploring The Future Of Healthcare AI

InnovationRx is your weekly digest of healthcare news. Sign up!

United statesElon muskEli lillyJohn brownsteinLos angelesHarjinder sandhuLife sciences platforms at microsoftGlobal health innovation fundSupreme courtNovo nordiskNuance communicationsMainstay medical holdingsYale new haven healthDeerfield management companyLife sciences platformsBoston children